EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Experience of piloting BPaLM/BPaL for DR-TB care at selected sites in Pakistan

M.A. Khan, A. Ismail, A. Ghafoor, N. Khan, N. Muzaffar, F. Zafar, A. Gupta, S. Foraida, S. Juneja, R. Fatima, A.W. Khan, S. Shahid, M.A. Khan

IJTLD Open · 2024-11 · 1 (11) · 508-515

DOI: 10.5588/ijtldopen.24.0369 ↗
AbstractBibliografische Angaben

Abstract

SUMMARY BACKGROUND Pakistan ranks fourth globally in terms of high drug-resistant TB (DR-TB) burden, with approximately one-third of cases resistant to fluoroquinolones. Bedaquiline, pretomanid, linezolid and moxifloxacin (BPaLM/BPaL) offers an opportunity for most DR-TB patients to benefit from a shorter, all-oral, well-tolerated and more effective treatment. METHODS We conducted a retrospective cohort study to pilot the BPaLM/BPaL regimen at four selected sites in two provinces of Pakistan, i.e. Punjab and Khyber Pakhtunkhwa. Data were extracted and analysed using electronic medical records from the program. Descriptive statistics, survival analysis and binary logistic regression analysis were employed. RESULTS A total of 116 patients took treatment between October 2022 and February 2023. The treatment success rate was 96%, with 3% deaths and

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →